Table 1.
Overview of eight cohorts included in the meta-analysis
| Cohort | EUR | ALL | ||
|---|---|---|---|---|
| Cases (HLA-B*27; %) | Controls (HLA-B*27; %) | Cases (HLA-B*27; %) | Controls (HLA-B*27; %) | |
| UKB | 1260 (420; 33.5%) | 429,728 (35,066; 8.2%) | 1388 (424; 30.7%) | 452,976 (35,464; 7.9%) |
| GHS | 1007 (184; 18.3%) | 150,775 (12,216; 8.1%) | 1066 (188; 17.6%) | 159,644 (12,481; 7.8%) |
| UPenn-PMBB | 75 (13; 17.6%) | 28,426 (2133; 7.5%) | 233 (19; 8.2%) | 41,304 (2,352; 5.7%) |
| Sinai | 51 (13; 25.5%) | 10,681 (603; 5.7%) | 169 (20; 11.9%) | 29,676 (1,088; 3.7%) |
| MALMO | 114 (30; 26.3%) | 28,834 (2807; 9.7%) | 116 (30; 25.9%) | 29,121 (2,818; 9.7%) |
| MAYO | 331 (72; 21.8%) | 110,930 (9711; 8.8%) | 355 (74; 20.8%) | 115,063 (9,902; 8.6%) |
| UCLA | 161 (36; 22.4%) | 26,276 (1880; 7.2%) | 305 (54; 17.7%) | 39,912 (2,306; 5.8%) |
| Colorado | 181 (40; 22.1%) | 41,035 (3356; 8.2%) | 218 (47; 21.6%) | 48,853 (3,698; 7.6%) |
| Total | 3180 (808; 25.5%) | 826,685 (67,772; 8.2%) | 3850 (856; 22.3%) | 916,549 (70,109; 7.7%) |
Calculations of HLA-B*27 percentage of carriers include both cases and controls, but exclude samples with missing HLA-B*27 information (detailed in Supplementary Data 9). UKB U.K. Biobank, GHS Geisinger Health System MyCode, UPenn-PMBB The Penn Medicine BioBank, Sinai Mount Sinai BioMe BioBank, MALMO Malmö Diet and Cancer Study, Colorado Colorado Center for Personalized Medicine Biobank, UCLA UCLA ATLAS Community Health Initiative Biobank, MAYO MAYO-Clinic RGC Project Generation.